Clinical/Research Interests

Mechanisms of cellular response to oxidative stress, drug and carcinogen metabolism, pharmacokinetics assay development, mass spectrometry, HPLC.

Dr. Henderson is pursuing the development of advanced diagnostics with the goal of predicting patient response to cancer drugs prior to initiation of toxic chemotherapy. The diagnostics development is enabled by accelerator mass spectrometry (AMS), an ultrasensitive technology for detecting rare isotopes such as radiocarbon and tritium in biological samples. AMS is also useful for measuring pharmacokinetics of small drug doses in humans, which Dr. Henderson is applying to drug development and drug formulation studies. Another project involves the incorporation of hydrophobic drugs and membrane proteins into nanoparticles made of apolipoproteins and phospholipids called nanolipoproitein particles (NLPs). NLPs closely mimic the cellular membrane bilayer, and render hydrophobic molecules water soluble. Dr. Henderson is using NLPs for drug delivery and protein biochemistry studies that are related to breast cancer research.

Specialty:

Education:

Education:

Professional Memberships:

Select Recent Publications:

Mundt, J.M.; Hah, S.S.; Sumbad, R.A.; Schramm, V.A.; Henderson, P.T. DNA and RNA requires purine nucleoside phosphorylase in MCF-7 cells, Nucleic Acids Research, 2008, Vol. 36, No. 1 228-236.

Hah, S.S.; Sumbad, R.A.; de Vere White, R.; Turteltaub, K.W.; Henderson, P.T. Characterization of Oxaliplatin-DNA Adduct Formation in DNA and Differentiation of Cancer Cell Drug Sensitivity at Microdose Concentrations, Chemical Research in Toxicology 2007, 20(12), 1745-1751.

Chromy, B.; Arroyo, E.; Blanchette, C.; Bench, G.; Benner, H; Cappuccio, J.; Coleman, M.; Henderson, P.; Kuhn, E.; Brad Pesavento, B.; Segelke, B.; Sulchek, T.; Walsworth, V.; Paul Hoeprich, P. Different Apolipoproteins Impact Nanolipoprotein Particle Formation Journal of the American Chemical Society, 2007,129(46):14348-54.

Hah, S.S.; Mundt, J.M.; Kim, H.M.; Sumbad, R.A.; Turteltaub, K.W.; Henderson, P.T. Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry, Proceedings of the National Academy of Sciences,USA, 2007, 104, 27, 11203-11208 (cover article).

Hah, S.S.; Mundt, J.M.; Ubick, E.A.; Turteltaub, K.W.; Gregg, J.P.; Henderson, P.T. A protocol for quantification of radiolabeled nucleoside incorporation into DNA by accelerator mass spectrometry Nuclear Instrumentation Methods, Physics Research B, 2007, 259, 763-766.

Hah, S.S.; Stivers, K.M.; de Vere White, R.; Henderson, P.T. Kinetics of Carboplatin-DNA Binding in Genomic DNA and Bladder Cancer Cells As Determined by Accelerator Mass Spectrometry, Chemical Research in Toxicology, 2006, 19, 622-626.

Henderson, P.T.; Neeley, W.N. Delaney, J.C.; Gu, F.; Tannenbaum, S.R.; Essigmann, J.M. Urea lesion derived from hydrolysis of oxaluric acid in DNA: a potent source of G?C mutations by peroxynitrite oxidation of guanine, Chemical Research in Toxicology, 2005, 18, 12-18.

Hah, S. S.; Kim, H. M.; Sumbad, R. A.; Henderson, P. T. Hydantoin derivative formation from oxidation of 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxodG) and incorporation of 14C-labeled 8-oxodG into the DNA of human breast cancer cells, Bioorganic and Medicinal Chemistry Letters 2005, 15, 3627-3631.

Neeley, W.N.; Delaney, J.C.; Henderson, P.T.; Essigmann, J.M. In Vivo Bypass Efficiencies and Mutational Signatures of the Guanine Oxidation Products 2-Aminoimidazolone and 5-Guanidino-4-nitroimidazole, Journal of Biological Chemistry, 2004, 279(42), 43568-43573.

Neeley, W.L.; Delaney, J.C.; Henderson, P.T.; Essigmann, J.M. In Vivo Bypass Efficiencies and Mutational Signatures of the Guanine Oxidation Products 2-Aminoimidazolone and 5-Guanidino-4-nitroimidazole, Journal of Biological Chemistry, 2004, 279(42), 43568-43573.